Teleflex Announces Tenth Anniversary of GuideLiner® Catheter Product Line
September 25 2019 - 6:45AM
Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical technologies, today announced the tenth anniversary of its
industry-leading GuideLiner
® Catheter.
Released in November 2009, the GuideLiner®
Catheter revolutionized the concept of guide extension in the
medical device industry. Since that time, the company has sold more
than 1 million GuideLiner® Catheters—from three
product generations—across 62 countries, including more than
550,000 units in North America alone.
Guide extension catheters are designed to give
interventionalists the support they to need to navigate to
diseased, calcified lesions and deliver other devices to treat a
diseased vessel. “In the current practice of interventional
cardiology, we increasingly deal with tortuous and calcified
vessels,” said Dr. Amir Ravandi, interventional cardiologist and
associate professor of medicine at St. Boniface Hospital, Winnipeg,
Manitoba. “The GuideLiner V3 Catheter offers improved guide
catheter support, allowing us to deliver devices with ease to treat
these complex vessels.” 1
The GuideLiner® V3 Catheter’s coil-reinforced
guide extension offers greater longitudinal flexibility and shape
retention that is less kinkable than braid-reinforced designs.2 “In
developing the GuideLiner V3 Catheter, we understood that
physicians wanted flexibility for easy, atraumatic delivery,
without sacrificing the very backup support they sought in a
device,” said Josh Brenizer, Principal R&D Engineer for the
GuideLiner® V3 Catheter. “A fully
hydrophilic-coated extension can improve deliverability, but can
result in the loss of valuable backup support within the guide.3
With this in mind, we selected a silicone coating that testing has
shown provides superior back-up support, while still providing the
deliverability to get the GuideLiner V3 Catheter to where it needs
to go.”
In addition, the GuideLiner® V3 Catheter’s
unique half-pipe channel is designed to minimize device/collar
interactions by directing and aligning the devices through the
collar transition, facilitating smooth device entry and seamless
delivery. No collar separations have been reported in PCI for the
GuideLiner® V3 Catheter.4
The GuideLiner® V3 Catheter will be featured in
Teleflex booth 1251 at TCT 2019, September 25-29 at the Moscone
Center in San Francisco. For more information about the
GuideLiner® V3 Catheter, visit
Teleflex.link/guideliner.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed
to improve the health and quality of people’s lives. We apply
purpose driven innovation – a relentless pursuit of identifying
unmet clinical needs – to benefit patients and healthcare
providers. Our portfolio is diverse, with solutions in the fields
of vascular access, interventional cardiology and radiology,
anesthesia, emergency medicine, surgical, urology and respiratory
care. Teleflex employees worldwide are united in the understanding
that what we do every day makes a difference. For more information,
please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rusch®, UroLift®, and Weck® – trusted brands united
by a common sense of purpose.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Any forward-looking statements contained herein are
based on our management's current beliefs and expectations, but are
subject to a number of risks, uncertainties and changes in
circumstances, which may cause actual results or company actions to
differ materially from what is expressed or implied by these
statements. These risks and uncertainties are identified and
described in more detail in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, the Teleflex logo, GuideLiner, Arrow, Deknatel, Hudson
RCI, LMA, Pilling, Rusch, UroLift, and Weck are trademarks or
registered trademarks of Teleflex Incorporated or its affiliates,
in the U.S. and/or other countries.
© 2019 Teleflex Incorporated. All rights reserved. MC-005910 Rev
0
References:
- These statements reflect the personal experience and opinion of
the physician.
- All values and relative product comparisons are based on bench
test data averages (n≥5) of competitive models and are analyzed
with a minimum of 95% confidence as a percentage of the means.
Bench text results may not necessarily be indicative of clinical
performance. Testing completed by Teleflex. Data on
file.
- Testing completed by Teleflex. Data on file. Comparative data
may not necessarily be indicative of clinical
performance.
- Based upon a review of all device experience reports for
coronary usage of GuideLiner® V3 Catheters from launch through July
2019. Data on file.
Source:
Teleflex IncorporatedJake ElguiczeTreasurer and Vice President,
Investor Relations610-948-2836
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024